Immunotherapy Drug Articles & Analysis
5 articles found
The classification of anti-tumor APIs often falls into four main types: chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormone therapy drugs. ...
The company has recently launched TCR-seq, a powerful service that enables rapid and efficient analysis of T-cell receptor (TCR) diversity and clonality, providing critical support for immune and cancer research. As immunotherapy gains widespread use, increasing attention is being focused on T-cell clone diversity and clonality, which is crucial for evaluating the effectiveness ...
Results have been shown to be safe from several clinical trials of immunotherapy drugs targeting mesothelin, including immunotoxin therapy, monoclonal antibodies, vaccines, antibody-conjugated drugs, CAR T cells, CAR-NK cells, and α-targeted therapies. ...
A study conducted under the Lung Cancer Master Protocol (Lung-MAP) found that when treated with a combination of ramuzumab (Cyramza) and Keytruda, Patients with advanced NSCLC whose cancer progressed during prior immunotherapy lived significantly longer than when treated with one of the current standard therapies for this cancer. ...
Their goal is to identify markers found on the surface of patients' immune cells that are associated with the response of these patients to immunotherapy—mainly PD-1 targeted drugs such as nivolumab (trade name Opdivo) and pembrolizumab (trade name Keytruda). ...